Evidence map›Paper›PMID 37252916›Full record

ArticlePloS one2023

Reassessing the adrenomedullin scavenging function of ACKR3 in lymphatic endothelial cells.

Elena C Sigmund, Aline Bauer, Barbara D Jakobs, Hazal Tatliadim, Carlotta Tacconi, Marcus Thelen, Daniel F Legler, Cornelia Halin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Atypical chemokine receptors in the immune system.Nature reviews. Immunology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Elena C SigmundInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
Aline BauerInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
Barbara D JakobsBiotechnology Institute Thurgau (BITg), University of Konstanz, Kreuzlingen, Switzerland.
Hazal TatliadimInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
Carlotta TacconiInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID 0000-0002-6431-7555
Marcus ThelenInstitute for Research in Biomedicine (IRB), Università della Svizzera Italiana, Bellinzona, Switzerland.
Daniel F LeglerBiotechnology Institute Thurgau (BITg), University of Konstanz, Kreuzlingen, Switzerland.
Cornelia HalinInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID 0000-0002-0997-1861
ETH Zurich · CHBiotechnology Institute Thurgau · CHUniversità della Svizzera italiana · CHUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atypical chemokine receptor 3 (ACKR3) is a scavenger of the chemokines CXCL11 and CXCL12 and of several opioid peptides. Additional evidence indicates that ACKR3 binds two other non-chemokine ligands, namely the peptide hormone adrenomedullin (AM) and derivatives of the proadrenomedullin N-terminal 20 peptide (PAMP). AM exhibits multiple functions in the cardiovascular system and is essential for embryonic lymphangiogenesis in mice. Interestingly, AM-overexpressing and ACKR3-deficient mouse embryos both display lymphatic hyperplasia. Moreover, in vitro evidence suggested that lymphatic endothelial cells (LECs), which express ACKR3, scavenge AM and thereby reduce AM-induced lymphangiogenic responses. Together, these observations have led to the conclusion that ACKR3-mediated AM scavenging by LECs serves to prevent overshooting AM-induced lymphangiogenesis and lymphatic hyperplasia. Here, we further investigated AM scavenging by ACKR3 in HEK293 cells and in human primary dermal LECs obtained from three different sources in vitro. LECs efficiently bound and scavenged fluorescent CXCL12 or a CXCL11/12 chimeric chemokine in an ACKR3-dependent manner. Conversely, addition of AM induced LEC proliferation but AM internalization was found to be independent of ACKR3. Similarly, ectopic expression of ACKR3 in HEK293 cells did not result in AM internalization, but the latter was avidly induced upon co-transfecting HEK293 cells with the canonical AM receptors, consisting of calcitonin receptor-like receptor (CALCRL) and receptor activity-modifying protein (RAMP)2 or RAMP3. Together, these findings indicate that ACKR3-dependent scavenging of AM by human LECs does not occur at ligand concentrations sufficient to trigger AM-induced responses mediated by canonical AM receptors.

Indexed as

AdrenomedullinEndothelial CellsReceptors, CXCRChemokine CXCL11HEK293 CellsHumansHyperplasiaReceptors, AdrenomedullinACKR3 protein, humanAdrenomedullinChemokine CXCL11Receptors, AdrenomedullinReceptors, CXCR

Identifiers

PMID37252916
PMCPMC10228790
OpenAlexW4378782013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.